Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: food – Page 137

Biotechnology is a curious marriage of two seemingly disparate worlds. On one end, we have living organisms—wild, unpredictable celestial creations that can probably never be understood or appreciated enough, while on the other is technology—a cold, artificial entity that exists to bring convenience, structure and mathematical certainty in human lives. The contrast works well in combination, though, with biotechnology being an indispensable part of both healthcare and medicine. In addition to those two, there are several other applications in which biotechnology plays a central role—deep-sea exploration, protein synthesis, food quality regulation and preventing environmental degradation. The increasing involvement of AI in biotechnology is one of the main reasons for its growing scope of applications.

So, how exactly does AI impact biotechnology? For starters, AI fits in neatly with the dichotomous nature of biotechnology. After all, the technology contains a duality of its own—machine-like efficiency combined with the quaintly animalistic unpredictability in the way it works. In general terms, businesses and experts involved in biotechnology use AI to improve the quality of research and for improving compliance with regulatory standards.

More specifically, AI improves data capturing, analysis and pattern recognition in the following biotechnology-based applications:

Read more | >

Part 2

In this video Dr. Lustgarten goes into more detail on what he tracks and how he does the analysis of the results. He emphasizes the importance of running your own tests, to not only look at one biomarker but to then combine that marker with other biomarkers, looking for what is optimal for you.

Dr. Michael Lustgarten is a scientist at the Tufts University Human Nutrition Research Center on Aging in Boston, Massachusetts. His research currently focuses on the role of the gut microbiome and serum metabolome on muscle mass and function in older adults.

Continue reading “N of 1 Extend Lifespan Experiment: Evaluating Progress | Dr Lustgarten Interview Series 3 Ep 2” | >

A new fabrication technique produces low-voltage, power-dense artificial muscles that improve the performance of flying microrobots.

When it comes to robots, bigger isn’t always better. Someday, a swarm of insect-sized robots might pollinate a field of crops or search for survivors amid the rubble of a collapsed building.

MIT.

Read more | >

AI doesn’t just want to eat your lunch — sometimes it wants to deliver it, too.

Driverless tech provider Motional and Uber Eats plan to add a dash of autonomy to food delivery next year in Santa Monica, serving up meal kits from select restaurants. The news was first reported by AiThority.

The plan is for food deliveries to come via Motional’s all-electric Hyundai IONIQ 5-based robotaxis. Motional said this will be the first time its vehicles are used to deliver food. It’s not clear whether humans or robots will bring the meal kits to customers’ doorsteps.

Read more | >

In this video Dr. Lustgarten introduces his N of 1 experiment and gives an overview of the processes that he follows. He also discusses why he thinks it is important to track your own markers and not just rely on published trials.

Dr. Michael Lustgarten is a scientist at the Tufts University Human Nutrition Research Center on Aging in Boston, Massachusetts. His research currently focuses on the role of the gut microbiome and serum metabolome on muscle mass and function in older adults.
In this series of interviews Dr Lustgarten shares his experience with his rigorous n of 1 experiment over the last 7 years and shows how we or anyone can conduct a similar trial by tracking food, exercise and sleep, measure results and derive relationships between them, with a goal of extending our healthspan.

Dr Lustgarten’s channel on YouTube: https://www.youtube.com/channel/UCT1UMLpZ_CrQ_8I431K0b-g.

***************************************************************

Continue reading “N Of 1 Extend Lifespan Experiment: How To Start | Dr Michael Lustgarten Interview Series 3 Ep 1” | >

Many intractable diseases are the result of a genetic mutation. Genome editing technology promises to correct the mutation and thus new treatments for patients. However, getting the technology to the cells that need the correction remains a major challenge. A new study led by CiRA Junior Associate Professor Akitsu Hotta and in collaboration with Takeda Pharmaceutical Company Limited as part of the T-CiRA Joint Research Program reports how lipid nanoparticles provide an effective means for the delivery to treat Duchenne muscular dystrophy (DMD) in mice.

Last year’s Nobel Prize for Chemistry to the discoverers of CRISPR-Cas9 cemented the impact of genome editing technology. While CRISPR-Cas9 can be applied to agriculture and livestock for more nutritious food and robust crops, most media attention is on its medical potential. DMD is just one of the many diseases that researchers foresee a treatment using CRISPR-Cas9.

“Oligonucleotide drugs are now available for DMD, but their effects are transient, so the patient has to undergo weekly treatments. On the other hand, CRISPR-Cas9 effects are long lasting,” said Hotta.

Read more | >

According to a news release by The University of Manchester, a groundbreaking study published in the journal Scientific Reports provides new evidence that helps us to understand the asteroid impact that brought an end to 75 percent of life on Earth, including non-avian dinosaurs, at the Cretaceous-Paleogene transition 66 million years ago.

This project has been a huge undertaking but well worth it. For so many years we’ve collected and processed the data, and now we have compelling evidence that changes how we think of the KPg event, but can simultaneously help us better prepare for future ecological and environmental hazards.

Time of year plays an important role in many biological functions— reproduction, available food sources, feeding strategies, host-parasite interactions, seasonal dormancy, breeding patterns, to name a few. It is hence no surprise that the time of year for a global-scale disaster can play a big role in how harshly it impacts life. The seasonal timing of the Chicxulub impact has therefore been a critical question for the story of the end-Cretaceous extinction. Until now the answer to that question has remained unclear.

Read more | >

A new technology is allowing one company to produce full-spectrum cannabis without growing the plant itself.

Sounds like something out of a science fiction movie, but it’s very real. In what could be a global first, this week, a publicly traded Canadian-Israeli biotech firm company, BioHarvest Sciences, will announce that it has managed to produce at least 10kg of full-spectrum cannabis without the plant itself.

According to information procured exclusively, the biomass in question was created using the company’s proprietary BioFarming technology platform, which allows it to grow natural plant cells in bioreactors. In addition, management assures, the product is not genetically modified, and is “uniquely consistent and clean.” This could provide an interesting solution to two of the cannabis industry’s main pain points: product variability and contamination — the aseptic, controlled environment means the product isn’t affected by fungi, yeast, mold or any other contaminants or pesticides.

Exclusive details on breakthrough plant technology that could revolutionize medicine, food, land conservation and more.

Continue reading “Producing Cannabis Biomass Without Growing A Cannabis Plant: How One Company Is Doing It” | >